Profile data is unavailable for this security.
About the company
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
- Revenue in SEK (TTM)0.00
- Net income in SEK-88.76m
- Incorporated1999
- Employees13.00
- LocationAscelia Pharma ABHyllie Boulevard 34MALMO 215 32SwedenSWE
- Phone+46 462863760
- Websitehttps://www.ascelia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sprint Bioscience AB | 68.36m | 8.77m | 100.54m | 36.00 | 11.47 | 4.07 | 10.78 | 1.47 | 0.1256 | 0.1256 | 0.9791 | 0.3538 | 1.58 | -- | 11.45 | 2,441,286.00 | 20.29 | -71.22 | 43.20 | -113.71 | 80.06 | 62.75 | 12.83 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
| NextCell Pharma AB | 12.45m | -39.37m | 109.64m | -- | -- | 1.17 | -- | 8.81 | -0.9046 | -0.9046 | 0.286 | 1.28 | 0.1406 | 14.06 | 7.20 | -- | -44.45 | -34.92 | -50.09 | -37.06 | 12.04 | -68.21 | -316.25 | -538.60 | 4.36 | -- | 0.00 | -- | 80.96 | 72.85 | -15.21 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 1.47m | -35.58m | 116.30m | 12.00 | -- | 2.19 | -- | 79.33 | -0.3129 | -0.3129 | 0.0113 | 0.1525 | 0.0324 | -- | 9.91 | 112,769.20 | -78.60 | -20.19 | -93.27 | -20.97 | -5.25 | -- | -2,426.88 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| AroCell AB (publ) | 44.79m | -56.13m | 124.40m | -- | -- | 0.8123 | -- | 2.78 | -0.2437 | -0.2437 | 0.1944 | 0.6648 | 0.2325 | 5.82 | 5.63 | -- | -29.14 | -29.25 | -31.00 | -31.37 | 1.88 | -9.85 | -125.33 | -231.19 | 5.16 | -- | 0.00 | -- | 16.37 | 122.92 | -0.5494 | -- | -- | -- |
| Coegin Pharma AB | 0.00 | -27.98m | 140.37m | 0.00 | -- | 10.78 | -- | -- | -2.65 | -2.65 | 0.00 | 0.6403 | 0.00 | -- | -- | -- | -125.24 | -122.02 | -201.53 | -154.70 | -- | -- | -- | -28,466.75 | -- | -170.65 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
| Biosergen AB | 0.00 | -28.90m | 149.88m | 4.00 | -- | 2.16 | -- | -- | -0.3579 | -0.3579 | 0.00 | 0.2497 | 0.00 | -- | -- | 0.00 | -113.63 | -- | -147.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -88.76m | 156.80m | 13.00 | -- | 2.58 | -- | -- | -2.63 | -2.63 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -65.17 | -- | -78.39 | -- | -- | -- | -- | -- | -- | -- | 0.2302 | -- | -- | -- | 16.72 | -- | -- | -- |
| Xintela AB | 377.00k | -49.24m | 166.08m | -- | -- | -- | -- | 440.53 | -0.1217 | -0.1217 | 0.0008 | -0.0136 | 0.0193 | -- | 0.0447 | -- | -252.59 | -181.06 | -- | -391.61 | 100.00 | -- | -13,061.54 | -235,894.00 | -- | -49.47 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| AlzeCure Pharma AB | 0.00 | -37.43m | 168.32m | 11.00 | -- | 9.21 | -- | -- | -0.5685 | -0.5685 | 0.00 | 0.2122 | 0.00 | -- | -- | 0.00 | -92.80 | -52.78 | -115.25 | -57.01 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.91 | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -136.81m | 170.82m | 16.00 | -- | 1.15 | -- | -- | -0.3953 | -0.3953 | 0.00 | 0.2488 | 0.00 | -- | -- | 0.00 | -64.42 | -- | -84.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| Active Biotech AB publ | 0.00 | -44.80m | 177.98m | 8.00 | -- | 8.85 | -- | -- | -0.1651 | -0.1651 | 0.00 | 0.0556 | 0.00 | -- | -- | -- | -122.57 | -57.97 | -179.56 | -97.83 | -- | -- | -- | -1,454.61 | -- | -- | 0.1145 | -- | -- | -- | 21.54 | -- | -- | -- |
| SenzaGen AB | -100.00bn | -100.00bn | 206.53m | 32.00 | -- | 2.58 | -- | -- | -- | -- | -- | 2.71 | -- | -- | -- | -- | -- | -25.84 | -- | -29.85 | -- | 68.62 | -- | -132.29 | 1.24 | -- | 0.0368 | -- | 19.39 | 90.32 | 11.30 | -- | -21.10 | -- |
| Kancera AB | 0.00 | -60.35m | 208.68m | 5.00 | -- | 2.22 | -- | -- | -0.7267 | -0.7267 | 0.00 | 0.7749 | 0.00 | -- | -- | 0.00 | -52.92 | -54.82 | -65.84 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
| Alzinova AB | 300.00k | -17.17m | 210.06m | 5.00 | -- | 1.28 | -- | 700.20 | -0.3221 | -0.3221 | 0.0056 | 1.98 | 0.0027 | -- | 0.4459 | 60,000.00 | -15.32 | -10.77 | -16.22 | -11.27 | 6,018.45 | -- | -5,723.82 | -18,447.90 | -- | -- | 0.0073 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
| Biovica International AB | 7.29m | -124.82m | 218.96m | 32.00 | -- | 2.45 | -- | 30.03 | -2.12 | -2.12 | 0.1218 | 1.15 | 0.048 | 0.2322 | 6.50 | 227,843.80 | -82.20 | -51.94 | -99.16 | -58.18 | 94.34 | 181.68 | -1,712.00 | -2,217.41 | 3.04 | -- | 0.0749 | -- | 115.49 | 19.39 | -12.97 | -- | -54.31 | -- |
Data as of Jul 26 2024. Currency figures normalised to Ascelia Pharma AB's reporting currency: Swedish Krona SEK
12.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2023 | 2.71m | 8.03% |
| Healthinvest Partners ABas of 30 Jun 2022 | 700.00k | 2.07% |
| FCG Fonder ABas of 31 Dec 2023 | 436.17k | 1.29% |
| Handelsbanken Fonder ABas of 30 Jun 2024 | 209.36k | 0.62% |
| SEB Investment Management ABas of 28 Jun 2024 | 166.01k | 0.49% |
| Skandia Investment Management ABas of 31 May 2024 | 32.94k | 0.10% |
| AIFM Capital ABas of 31 Dec 2021 | 30.13k | 0.09% |
| Storebrand Asset Management ASas of 30 Jun 2024 | 2.75k | 0.01% |
More ▼
Data from 31 Dec 2021 - 30 Jun 2024Source: FactSet Research Systems Inc.
